Early FMT for C.Difficile

Completed · Phase 1/Phase 2

Conditions studied: Clostridium Difficile

In brief

Clostridium difficile infection (CDI) has increased worldwide in both frequency and severity. It is the leading cause of hospital acquired infection in developed countries and has been associated with at least 14,000 deaths per year in the United States. With 3 million cases/ year, the annual cost for treating the infection is exceeding 3 billion dollars. It can also have a profound negative impact on quality of life. The investigators believe that patients who are at high risk of relapse after a first CDI episode would benefit from early fecal microbial transplant (FMT). The proposed study will produce preliminary data regarding safety and efficacy and potential for cost effectiveness for the use of early fecal transplant in those patients with their first episode of non-refractory CDI who are predicted to have a high rate of recurrence based on previously published risk factors. The investigators will be better prepared to test the efficacy of this approach in a future multicenter clinical trial in a randomized controlled fashion. The purpose of this study is to compare the effectiveness and safety of early fecal transplant using donor stool from a healthy person in a group of patients who are diagnosed with their first episode of Clostridium difficile infection and are predicted to have a high chance of the infection returning against a similar group of patients who receive current standard of care for treatment of C.difficile. The investigators hypothesize: * that clinical remission rates at 12 weeks as noted by absence of clinical symptoms and/or negative C.difficile stool polymerase chain reaction (PCR) will be greater in the experimental arm compared to the control arm * that patients in the experimental group will have a low microbial diversity prior to FMT but will exhibit a high microbial diversity after the FMT that resembles the respective donor * that the microbial diversity will be diminished in both groups at the time of enrollment, but the experimental group will exhibit a higher microbial diversity compared to the control population at 12 weeks * that patients in both groups will exhibit poor quality of life at the time of enrollment, however, the experimental group will demonstrate higher quality of life compared to the control group at follow up after completion of treatment * that costs incurred by the experimental group will be less than the control group

Key facts

Study ID

NCT02465463

Run by

Emory University

People needed

13

Starts

2015-06-01

Expected to finish

2016-11-01

Last updated by the study team

2018-01-31

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet all of the following criteria to be eligible for the study:
• First or second episode of CDI responding to therapy
• Must have 2 or more of the following criteria:
• Age >65
• Severe underlying disease (measured by Horn index score of 3 or 4)
• Additional non-C.difficile antibiotic exposure during CDI episode
• Use of antacids
• Previous episode of CDI
• Willingness to accept a fecal product made using unrelated donor stool and to comply with study protocol requirements
• Able to give informed consent
• Chronic infection with HIV, HBV, HCV is permitted unless the viral infection compromises the ability of the patient to safely participate in the study. Patients with a CD4 count <200 and/ or AIDS defining illness or decompensated cirrhosis will not be eligible for the study.
• Life expectancy >4 months

You may not qualify if…

• Any of the following: acute leukemia, history of allogenic or recent (within 6 months) autologous bone marrow transplant, or use of cytotoxic chemotherapy within 2 months
• ANC <1000/mm\^3
• History of inflammatory bowel disease
• History of total colectomy
• Pregnant or nursing mothers
• History of significant food allergy to foods not excluded from the donor diet
• Patient has any other condition that, in the opinion of the Investigator, would jeopardize the safety or rights of the subject participating in the study, would make it unlikely for the subject to complete the study, or would confound the results of the study
• Patients who are aged 80 years or greater
• Patients who are incarcerated
• Patient with cognitive impairment or severe neuropsychiatric co morbidities who are incapable of giving consent
• Inherited/primary immune disorders
• Patients who are unwilling or unable to undergo sigmoidoscopy
• Unable to comply with protocol requirements
• Patients with untreated, in-situ colorectal cancer

Where it is running

• Emory University — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.